FOXO4-DRI
FOXO4-DRI (D-Retro-Inverso) is an experimental peptide designed to target senescent cells—cells that stop dividing but remain metabolically active, contributing to aging, inflammation, and chronic disease. By disrupting the FOXO4-p53 interaction, FOXO4-DRI may trigger selective apoptosis of senescent cells while sparing healthy, functional cells. First reported in 2017 studies, it has attracted major interest in the longevity and anti-aging research community.
FOXO4-DRI (D-Retro-Inverso) is an experimental peptide designed to target senescent cells-cells that stop dividing but remain metabolically active, contributing to aging, inflammation, and chronic disease. By disrupting the FOXO4-p53 interaction, FOXO4-DRI may trigger selective apoptosis of senescent cells while sparing healthy, functional cells. First reported in 2017 studies, it has attracted major interest in the longevity and anti-aging research community.
Chemical info
• Name: FOXO4-DRI (D-Retro-Inverso peptide)
• CAS Number: 2460055-10-9
• Type: Synthetic peptide
• Appearance: White/off-white lyophilized powder
• Purity: ≥98% (HPLC tested)
• Storage: –20°C, dry and dark; avoid repeated freeze-thaw cycles
• Form: Research peptide only
Research & Applications
• Senolytic Effects:
Selectively clears senescent cells in cell and animal models.
• Anti-Aging Research:
Investigated for extending healthspan by reducing inflammatory senescent burden.
• Hormone & Energy Balance:
Mouse studies suggest FOXO4-DRI may restore testicular function and testosterone production in aged males.
• Tissue Repair:
Studied in cartilage and lung fibrosis models, reducing inflammation and senescence markers.
• Cancer & Inflammation:
Experimental work shows FOXO4-DRI may improve tissue recovery after chemotherapy or radiation by clearing therapy-induced senescent cells.
FOXO4-DRI in Cancer Research
FOXO4-DRI has been explored in oncology for its ability to selectively remove senescent cells. Senescent cells can be beneficial in halting tumor growth, but their secretions (SASP: senescence-associated secretory phenotype) may fuel cancer progression and chronic inflammation. FOXO4-DRI is being studied as a senolytic adjuvant-helping to clear therapy-induced senescent cells after chemotherapy or radiation, potentially reducing side effects and improving tissue recovery. However, it is not a stand-alone cancer cure, and research remains in preclinical stages.
Comparison: FOXO4-DRI vs Fisetin vs Dasatinib+Quercetin
|
Feature |
FOXO4-DRI |
Fisetin |
Dasatinib + Quercetin |
|
CAS Number |
2460055-10-9 |
528-48-3 |
302962-49-8 (Dasatinib) + 117-39-5 (Quercetin) |
|
Type |
Synthetic peptide (D-Retro-Inverso) |
Natural flavonoid (plant polyphenol) |
Tyrosine kinase inhibitor (Dasatinib) + flavonoid (Quercetin) |
|
Main Action |
Disrupts FOXO4-p53 to induce apoptosis of senescent cells |
Reduces senescent cells, antioxidant & anti-inflammatory |
Potent senolytic; clears senescent cells by targeting multiple pathways |
|
Research Areas |
Longevity, anti-aging, cancer adjuvant, fibrosis models |
Anti-aging, cognitive health, cardiovascular & metabolic support |
Senolytic cycles for anti-aging, experimental longevity therapies |
|
User Reports |
Experimental; some report injection site burning, limited systemic effects |
Generally well tolerated; taken orally as a supplement in community use |
Used in small senolytic trials; side effects include nausea, fatigue, cytotoxicity |
|
Approval Status |
Research only, not FDA-approved |
Dietary supplement status in many countries |
Dasatinib FDA-approved for leukemia (not senolysis); Quercetin is a supplement |
FOXO4-DRI Dosage
⚠️ Disclaimer: FOXO4-DRI is not FDA-approved. All dosing information is based on preclinical studies and anecdotal community reports only.
- Animal Studies: In mouse models, systemic injections were given at around 5 mg/kg twice weekly for several weeks, showing senescent cell clearance and tissue rejuvenation.
- Forum Mentions: Some self-experimenters mention ranges of 2–10 mg per dose by injection, though reports remain anecdotal with mixed outcomes.
- Delivery: Most effective in studies via injection. Oral or topical bioavailability is not supported by data.
- Cycling: Community discussions suggest senolytics may be best used intermittently (e.g., quarterly cycles) rather than continuously, mirroring protocols with compounds like Dasatinib + Quercetin or Fisetin.
Side Effects
• Burning/itching sensation at injection site.
• Possible immune or inflammatory flares (speculative).
• No large-scale human trials-effects and risks remain unknown.
• Community caution: Highly experimental, not comparable to approved therapies.
certifications
Shipping methods
| Country | Delivery time |
| Untied states | 7-15 DAYS |
| Australia | 7-12 DAYS |
| Germany | 7-12 DAYS |
| Canada | 8-10 DAYS |
| New zealand | 7-10 DAYS |
| Uk | 5-10 DAYS |
| Thailand | 5-8 DAYS |
| Malaysia | 5-8 DAYS |
| Vietnam | 5-8 DAYS |
The delivery time shown above is an estimate. Shipping routes and freight capacity may change from time to time. For the most accurate delivery schedule, please contact us directly.
Payment terms
Hot Tags: foxo4-dri, China foxo4-dri manufacturers, suppliers, factory, pnc 27 cancer, pnc 27 anti cancer peptide, foxo4 dri 10mg, anticancer peptides, foxo4 dri 5mg, anti cancer peptides
Send Inquiry
